Recent News
APG-2449 in Patients With Advanced Solid Tumors
APG-2449 is a novel, orally active, multi-targeted tyrosine kinase inhibitor, which inhibits FAK, ALK, and ROS1 with nanomolar potencies. In preclinical studies, APG-2449 demonstrated potent antiproliferative activity in various cancer cell lines as a single agent. In combination treatment, APG-2449 enhanced anti-proliferative activities of several chemotherapeutic and targeted agents. It is indicated that APG-2449 may have a broad therapeutic potential for the treatment of human cancer as a single agent and in combination with other classes of anticancer drugs. APG-2449 is intended for the treatment of patients with advanced solid tumors. Upon completion of the Phase 1 dose escalation study to establish the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), and/or recommended phase 2 dose (RP2D), several phase Ib/II studies will be implemented accordingly.
Palliative Care for Mesothelioma Patients Can Strengthen Mental Health
Even though palliative care is only for pain management and symptoms of an illness and not curative, it’s still an important part of the treatment regimen for those suffering from…
Hello world!
Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer
TC-210 T cells are a novel cell therapy that consists of autologous genetically engineered T cells expressing a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit which, upon expression, is incorporated into the endogenous T cell receptor (TCR) complex.
This Phase 1/2 study aims to establish the recommended Phase 2 dose (RP2D) and subsequently determine an overall response rate in patients with advanced mesothelin-expressing cancers.
Mesothelioma Patient Survival Potentially Doubles with Targeted Radiotherapy
Radiotherapy, also known as radiation therapy, is a type of cancer treatment that uses ionizing radiation to kill cancer cells by damaging the cell’s DNA. It can be used as…
INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)
The purpose of this study is to assess the safety and tolerability and to determine the recommended Phase 2 dose of INCMGA00012 in combination with common standard-of-care chemotherapy regimens in participants with advanced solid tumors.
Survival Factors for Mesothelioma Highlighted by University of Pittsburgh Medical Center
According to GLOBOCAN 2018 statistics, each year there are 30,443 mesothelioma cases worldwide, and of those 30,443, 25,576 pass away. With close to 85 percent of those diagnosed succumbing to…
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
The proposed study will evaluate the safety and feasibility of neoadjuvant nivolumab +/- ipilimumab in resectable MPM. In addition, maintenance nivolumab will be administered for 1 year following completion of standard bi-/tri-modality therapy.
Phase III Clinical Trial for Mesothelioma Available in 50 Locations Across the Globe
A Phase III clinical trial is now underway in the pivotal study of interferon alfa-2b gene therapy in pleural mesothelioma. After promising results from the Phase II clinical trial, scientists…
Nomogram May More Accurately Predict Mesothelioma Survival
Predicting pleural mesothelioma survival is a difficult task, as a number of factors are needed to make an accurate calculation. Currently, the TNM Staging system in place as one of…
